Logo image of ANNX

ANNEXON INC (ANNX) Stock Fundamental Analysis

NASDAQ:ANNX - Nasdaq - US03589W1027 - Common Stock

4.17  -0.03 (-0.71%)

After market: 4.3 +0.13 (+3.12%)

Fundamental Rating

3

Taking everything into account, ANNX scores 3 out of 10 in our fundamental rating. ANNX was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANNX as it has an excellent financial health rating, but there are worries on the profitability. ANNX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ANNX has reported negative net income.
In the past year ANNX has reported a negative cash flow from operations.
ANNX had negative earnings in each of the past 5 years.
In the past 5 years ANNX always reported negative operating cash flow.
ANNX Yearly Net Income VS EBIT VS OCF VS FCFANNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

The Return On Assets of ANNX (-31.02%) is better than 66.90% of its industry peers.
The Return On Equity of ANNX (-35.44%) is better than 75.40% of its industry peers.
Industry RankSector Rank
ROA -31.02%
ROE -35.44%
ROIC N/A
ROA(3y)-46.76%
ROA(5y)-47.35%
ROE(3y)-57.06%
ROE(5y)-55.92%
ROIC(3y)N/A
ROIC(5y)N/A
ANNX Yearly ROA, ROE, ROICANNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANNX Yearly Profit, Operating, Gross MarginsANNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

9

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANNX has more shares outstanding
The number of shares outstanding for ANNX has been reduced compared to 5 years ago.
ANNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANNX Yearly Shares OutstandingANNX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
ANNX Yearly Total Debt VS Total AssetsANNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 3.08 indicates that ANNX is not in any danger for bankruptcy at the moment.
ANNX's Altman-Z score of 3.08 is fine compared to the rest of the industry. ANNX outperforms 76.28% of its industry peers.
ANNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.08
ROIC/WACCN/A
WACCN/A
ANNX Yearly LT Debt VS Equity VS FCFANNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 17.18 indicates that ANNX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 17.18, ANNX belongs to the best of the industry, outperforming 92.04% of the companies in the same industry.
A Quick Ratio of 17.18 indicates that ANNX has no problem at all paying its short term obligations.
ANNX has a better Quick ratio (17.18) than 92.04% of its industry peers.
Industry RankSector Rank
Current Ratio 17.18
Quick Ratio 17.18
ANNX Yearly Current Assets VS Current LiabilitesANNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

ANNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.74%, which is quite impressive.
EPS 1Y (TTM)44.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 23.38% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y45.35%
EPS Next 2Y17.18%
EPS Next 3Y8.31%
EPS Next 5Y23.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANNX Yearly Revenue VS EstimatesANNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ANNX Yearly EPS VS EstimatesANNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANNX. In the last year negative earnings were reported.
Also next year ANNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANNX Price Earnings VS Forward Price EarningsANNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANNX Per share dataANNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.18%
EPS Next 3Y8.31%

More info and screens

0

5. Dividend

5.1 Amount

ANNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANNEXON INC

NASDAQ:ANNX (1/21/2025, 8:00:00 PM)

After market: 4.3 +0.13 (+3.12%)

4.17

-0.03 (-0.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners97.3%
Inst Owner Change0.15%
Ins Owners0.39%
Ins Owner Change20.85%
Market Cap444.48M
Analysts84.29
Price Target15.47 (270.98%)
Short Float %9.1%
Short Ratio6.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.35%
Min EPS beat(2)1.43%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)16.33%
Min EPS beat(4)1.43%
Max EPS beat(4)39.68%
EPS beat(8)8
Avg EPS beat(8)13.69%
EPS beat(12)10
Avg EPS beat(12)13.15%
EPS beat(16)10
Avg EPS beat(16)5.71%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.11%
PT rev (3m)-7.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.92%
EPS NY rev (1m)0%
EPS NY rev (3m)2.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.34
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)-1.05
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.99
OCFYN/A
SpS0
BVpS3.11
TBVpS3.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.02%
ROE -35.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.76%
ROA(5y)-47.35%
ROE(3y)-57.06%
ROE(5y)-55.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.56%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.18
Quick Ratio 17.18
Altman-Z 3.08
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)131.86%
Cap/Depr(5y)103.87%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.86%
EPS Next Y45.35%
EPS Next 2Y17.18%
EPS Next 3Y8.31%
EPS Next 5Y23.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.24%
OCF growth 3YN/A
OCF growth 5YN/A